Loading company…
Ventyx Biosciences develops immunology drugs for autoimmune and inflammatory conditions.
Ventyx Biosciences is a clinical-stage biotechnology company developing drugs for immunological conditions. Its pipeline includes programs targeting S1P1R, TYK2, NLRP3, cGAS and Gasdermin D. Founded in 2019, it is listed on the Nasdaq Global Select Market as VTY. In March 2024, it raised USD 100 million in PIPE funding.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in